# Valgen Medtech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/valgen-medtech

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Website: www.dinovamedtech.com/brand/content.aspx?id=67
- Latest round: Series B (May 6, 2021)
- Investors on record: 8

## About

Established in 2015 and based in Hangzhou, China, Valgen Medtech is a minimally invasive interventional device company. The company focuses on the treatment of mitral valve and tricuspid valve related technology innovation and product research and development, and provides systematic solutions. Valgen Medtech is committed to providing intelligent and integrated treatment solutions for patients with mitral valve disease worldwide. It headquartered in Hangzhou, and the R&D base is in Shenzhen. Also has offices in Beijing, Shanghai and Shenzhen.

The core products of Valgen Medtech mainly include: MitralStitch mitral valve repair system, Dragonfly mitral valve clamp system through femoral vein, Dragonfly tricuspid valve clamp system through femoral vein, etc. MitralStitch® adopts the minimally invasive repair of mitral regurgitation via the apical path, which can not only achieve the artificial chordae tendinous implantation alone, but also complete the mitral valve limb-to-margin repair alone, and meanwhile can complete the mitral valve limb-to-margin + chordae tendinous repair for complex lesions. It is the world's first and only innovative device that can provide three sets of clinical solutions for two surgical methods with one set of devices. MitralStitch® has achieved the physiological repair of surgical mitral valve in a minimally invasive way. It can be used for the repair of both organic and functional mitral regurgitation (DMR), which is the world's first technology. DragonFly™ uses femoral vein mitral valve edge to edge repair technology for the treatment of repaired DMR and FMR patients, including patients with complex DMR and patients with complex types of FMR with multiple complications.

Valgen Medtech will continue to devote itself to the development of Tool-box Concept for innovative minimally invasive mitral valve and tricuspid valve interventional therapy, in an effort to promote the development of the field of structural heart disease treatment.

## Funding rounds

- Series B, May 6, 2021 — Hong Shan, Qiming Venture Partners, Venus MedTech (HangZhou) Inc., DCP Capital, China Life Capital, Lake Bleu Capital, Ascendum Capital
- Series A, Jun 1, 2019 — Qiming Venture Partners, BioTrack Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Hong Shan — Series B
- Venus MedTech (HangZhou) Inc. — Series B
- DCP Capital (https://capitalatlas.ai/funds/dcp-capital) — Series B
- China Life Capital — Series B
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series B
- Ascendum Capital (https://capitalatlas.ai/funds/ascendum-capital) — Series B